On November 2, a panel of outside experts will review evidence for an experimental drug for depression, ALKS-5461, from Alkermes, and debate whether the FDA should approve the drug in 2019. The FDA is critical of the data Alkermes has accrued, the trial design it used, and whether the drug will be safe for patients to take. (Xconomy Boston)